Get the Stockscreener App
2.915
5.35%
-0.165
Prokidney Corp stock is traded at $2.915, with a volume of 357.65K.
It is down -5.35% in the last 24 hours and up +335.97% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$3.08
Open:
$3.07
24h Volume:
357.65K
Relative Volume:
0.03
Market Cap:
$438.95M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-5.114
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
-4.42%
1M Performance:
+335.97%
6M Performance:
+82.21%
1Y Performance:
+24.06%
1-Day Range:
$2.86
$3.07
1-Week Range:
$2.86
$3.50
52-Week Range:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
2.91 | 438.95M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.51 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.34 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.84 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
593.41 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.75 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
Does ProKidney Corp. stock perform well during market downturnsBuild wealth with reliable stock picks - jammulinksnews.com
What are the technical indicators suggesting about ProKidney Corp.AI Powered Forecasts With Proven Results - jammulinksnews.com
Is ProKidney Corp. stock overvalued or undervaluedAI Powered Entry Points That Work - jammulinksnews.com
Is it the right time to buy ProKidney Corp. stockOutstanding investment returns - jammulinksnews.com
ProKidney Shares Double on Strong Phase 2 Data for Kidney Disease Therapy - MSN
Key External Factors That Drive ProKidney Corp. Stock Price MovementsFree Stock Market Group - metal.it
Is ProKidney Corp. a growth stock or a value stockBuild a diversified portfolio for risk management - jammulinksnews.com
What makes ProKidney Corp. stock price move sharplyHigh-profit capital plays - jammulinksnews.com
How volatile is ProKidney Corp. stock compared to the marketCapitalize on emerging growth stocks - jammulinksnews.com
What are ProKidney Corp. company’s key revenue driversInvest smarter and grow your wealth faster - jammulinksnews.com
ProKidney Stock Skyrockets But Greensboro Is Still Empty Handed - Rhino Times
What analysts say about ProKidney Corp. stockUnmatched profit potential - PrintWeekIndia
Is ProKidney Corp. a good long term investmentFree Capital Allocation Plans - PrintWeekIndia
Published on: 2025-07-25 13:32:55 - PrintWeekIndia
Meet the Biotech Stock That Rocketed 775% Higher - AOL.com
Prokidney’s REACT Study: A Promising Step for Kidney Disease Treatment - TipRanks
What drives ProKidney Corp. stock priceHigh-octane financial growth - Autocar Professional
BlackRock, Inc. Reduces Stake in ProKidney Corp: A Strategic Por - GuruFocus
ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement - MSN
11 Best High Return Penny Stocks to Buy Now - Insider Monkey
JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK) - MSN
ProKidney Corp. Stock Analysis and ForecastDynamic profit expansion - Autocar Professional
JP Morgan Maintains Neutral Stance on ProKidney Corp., Citing Extended Timeline for Key Data - AInvest
ProKidney Corp. (PROK): Navigating Clinical Pivotality and Market Volatility in the Race for a CKD Breakthrough - AInvest
New Strong Buy Stocks for July 17th - MSN
10 Hot Penny Stocks to Invest in Now - Insider Monkey
ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? - Mitrade
Best Momentum Stocks to Buy for July 17th - Nasdaq
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
ProKidney gains pivotal therapy advancement step with FDA - Winston-Salem Journal
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.78%
0.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):